The kinetic component in drug discovery: Using the most basic pharmacological concepts to advance in selecting drugs to combat CNS diseases.
To reach the central nervous system (CNS) drugs must cross the brain-blood barrier and have appropriate pharmaco-kinetic/dynamic properties. However, in early drug discovery steps, selection of lead compounds, for example those targeting G-protein-coupled receptors (GPCRs), is made according to i) affinity, which is calculated in in vitro equilibrium conditions, and ii) potency, a signal transduction-related parameter, usually quantified at a fixed time-point in a heterologous expression system. This paper argues that kinetics must be considered already in early steps of lead compound selection. While affinity calculation requires the establishment of a ligand-receptor equilibrium the signal transduction starts as soon as the receptor senses the agonist. Taking cAMP production as example, the in vitro-measured cytoplasmic levels of this cyclic nucleotide do not depend on equilibrium dissociation constant, K D . Signaling occurs far from the equilibrium and correlates more with the binding rate (k on ) than with K D . Furthermore, residence time, a parameter to consider in lead optimization may significantly vary from in vitro to in vivo conditions. Results are discussed from the perspective of dopaminergic neurotransmission and dopamine-receptor-based drug discovery.